Diabetes complications in young adults with type 2 diabetes are occurring in unusually high rates, researchers reported at the American Diabetes Association annual meeting held earlier this month in San Francisco.
A single course of treatment with teplizumab delayed the development of type 1 diabetes in at-risk teens and children, shows a study presented at the American Diabetes Association annual meeting earlier this month.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
